Aptorum-DiamiR Merger Set to Close July 20, Finalizing Reverse Merger
APM sits 22% above its 52-week low of $0.65.
Summary
Aptorum Group expects its reverse merger with DiamiR Biosciences to close on or about July 20, 2026, following shareholder approval in June and multiple S-4 amendments. The merger includes a 1-for-10 reverse stock split and a Delaware redomestication. Post-merger, the combined company will be named Niki BioSolutions and trade on Nasdaq under the ticker NIKI. The transaction brings DiamiR's neurodegenerative disease diagnostics platform under Aptorum, shifting the company's focus to DiamiR's assets. The specific closing date removes uncertainty around timing, signaling positive execution.
At the time of this announcement, APM was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5M. The 52-week trading range was $0.65 to $4.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.